Abstract
The present review describes our approach to the development of a structurally unique class of 5- HT2A ligands. On the basis of an abbreviated graphics model of a 5-HT2A serotonin receptor, it was hypothesized that introduction of an additional aromatic ring might enhance the affinity of phenylethylamine (an agent that lacks significant affinity for the 5-HT2A receptors). Continued work with such structures, and the continual refinement of graphics receptor models, ultimately led to the identification of AMDA (27, 5-HT2A Ki = 20 nM). AMDA is a 5-HT2A antagonist that, unlike certain other tricyclic 5-HT2A antagonists, binds with very low affinity at dopamine D2 receptors, the serotonin transporter, and the norepinephrine transporter. Comparative structure-affinity studies indicate that AMDA binds in a manner distinct from the tricyclic antagonists Graphics models were employed to identify possible modes of binding. This investigation illustrates the impact of a combination of classical medicinal chemistry, receptor modeling, and molecular biology on novel drug design.
Keywords: Receptor Mutagenesis, Pharmacophore Models, Tricyclic Ring System, AMDA Analogs, aminomethyl rotation
Current Topics in Medicinal Chemistry
Title: Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New class of 5-HT2A Ligands
Volume: 2 Issue: 6
Author(s): Richard B. Westkaemper and Richard A. Glennon
Affiliation:
Keywords: Receptor Mutagenesis, Pharmacophore Models, Tricyclic Ring System, AMDA Analogs, aminomethyl rotation
Abstract: The present review describes our approach to the development of a structurally unique class of 5- HT2A ligands. On the basis of an abbreviated graphics model of a 5-HT2A serotonin receptor, it was hypothesized that introduction of an additional aromatic ring might enhance the affinity of phenylethylamine (an agent that lacks significant affinity for the 5-HT2A receptors). Continued work with such structures, and the continual refinement of graphics receptor models, ultimately led to the identification of AMDA (27, 5-HT2A Ki = 20 nM). AMDA is a 5-HT2A antagonist that, unlike certain other tricyclic 5-HT2A antagonists, binds with very low affinity at dopamine D2 receptors, the serotonin transporter, and the norepinephrine transporter. Comparative structure-affinity studies indicate that AMDA binds in a manner distinct from the tricyclic antagonists Graphics models were employed to identify possible modes of binding. This investigation illustrates the impact of a combination of classical medicinal chemistry, receptor modeling, and molecular biology on novel drug design.
Export Options
About this article
Cite this article as:
Westkaemper B. Richard and Glennon A. Richard, Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New class of 5-HT2A Ligands, Current Topics in Medicinal Chemistry 2002; 2 (6) . https://dx.doi.org/10.2174/1568026023393741
DOI https://dx.doi.org/10.2174/1568026023393741 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Current Neuropharmacology Conference Report
CNS & Neurological Disorders - Drug Targets Enhanced Oral Bioavailability of Oleanolic Acid in Rats with Phospholipid Complex
Letters in Drug Design & Discovery Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users
Current Pharmaceutical Design What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics Blocking the Link between Stimulus and Response at Previously Attended Locations: Evidence for Inhibitory Tagging Mechanism
Neuroscience and Biomedical Engineering (Discontinued) Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo
Current Drug Targets A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Screening Haemostasis – Looking for Global Assays: The Overall Haemostasis Potential (OHP) Method – A Possible Tool for Laboratory Investigation of Global Haemostasis in Both Hypo- and Hypercoagulable Conditions
Current Vascular Pharmacology Neuroimaging of Gut Nutrient Perception
Current Pharmaceutical Design Inhibition of the PERK-dependent Unfolded Protein Response Signaling Pathway Involved in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Central Nervous System Agents in Medicinal Chemistry Group I mGluR Induced LTD of NMDAR-synaptic Transmission at the Schaffer Collateral but not Temperoammonic Input to CA1
Current Neuropharmacology The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Cubic Phases, Cubosomes and Ethosomes for Cutaneous Application
Current Pharmaceutical Design β-Amyloid Fibrillation and/or Hyperhomocysteinemia Modify Striatal Patterns of Hyaluronic Acid and Dermatan Sulfate: Possible Role in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research